Assessing the State of Statin Therapy

Slides:

Advertisements

Similar presentations

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Advertisements

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Nutrient and Food Drug Interactions - Objectives

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Selection of NSAIDs for Osteoarthritis

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Statin Selection in the Elderly

Optimizing Statin Therapy

Managing Women Living With HIV Infection

An Endocrinology Clinic in Dyslipidemia

Statin Selection Aimed to Reduce New-Onset DM Risk:

Omega-3 Prescriptions vs Supplements in Practice

Tailoring Statin Therapy in Women

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Cholesteryl Ester Transfer Protein Inhibitors

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

American Heart Association Scientific Sessions

Obesity and Dyslipidemia: How Would You Treat?

Statins and the Elderly Patient

Statin Selection in Special Patient Populations: A Case Challenge

Understanding Statin Metabolism

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Diabetes Increases Risk of CVD

An Update on PCSK9 Inhibitors

Statins, HIV, and CVD.

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

Statins and Glucose Metabolism: Are All Agents Alike?

PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Personalizing Statin Therapy in Patients With HIV

A Journal Club on Lipid Management:

Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.

Early and Intensive T2D Management:

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Statins and HIV:.

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Lipid Clinic Challenge

Statins, HIV, and CVD.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Clinicians' Corner in Dyslipidemia

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

Statins, Obesity, and Hyperlipidemia

Glucose Management and Statin Therapy

How to Optimize Cholesterol Management in High-Risk CV Patients

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Reducing Risk for CV Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

New Lipid-Lowering Guidelines

Lipid Updates From Spring 2019

An Update on PCSK9 Inhibitors

Statins and Glucose Metabolism: An Endocrinology Perspective

Glucose Management and Statin Therapy

PCSK9 Inhibitors and Statin Intolerance

Updates on Dyslipidemia

Statin Selection in Patients With Pre-Diabetes: Case Considerations

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Presentation transcript:

Assessing the State of Statin Therapy

Goals

Multiple Challenges in Statin Selection

Risk Factors That Potentiate Atherogenesis

Proportion of US Adults at Recommended Lipid Levels in NHANES

2013 ACC/AHA Cholesterol Guidelines 4 Statin Benefit Groups Identified

Certain Statins Increase the Risk of New-Onset T2D

JUPITER: Rosuvastatin Therapy and T2D Risk

T2D Due to Statins -- Rare but Real

Must Know -- Then Do

Selected Drug Interactions That Increase Statin Levels

Selected Statin-Drug Interaction Dosing Adjustments

Selected Statin-Drug Interaction Dosing Adjustments (cont)

Statin-Associated Myopathy Risk Factors and CYP Associations

Grapefruit Juice and Cranberry Juice

Statins and Elderly Patients Who to Treat?

Polypharmacy

PROSPER Summary

HIV Infection and CV Risk

Arterial Inflammation Linked to Immune Activation in HIV Infection

REPRIEVE Trial Design

REPRIEVE Trial Hypotheses

Current Challenges in Preventing and Treating CHD in HIV Infection

Abbreviations